

20<sup>th</sup> May, 2019

The Dy. General Manager (Listing Dept.) BSE Limited., Corporate Relationship Dept., 1<sup>st</sup> Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001 (BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

## Sub.: Presentation to analysts on Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2019

The presentation on audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2019 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

5

MAHESH AGRAWAL VP (LEGAL) & COMPANY SECRETARY

Encl.: As above

#### TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Reg.Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com



# Q4 FY 2018-19

## **Consolidated Revenues for Q4 2018-19**

			(`Crore)
Particulars	Q4 1819	Q4 1718	Gr%
India	754	693	9%
US	372	307	21%
Brazil	205	215	-4%
Germany	240	234	2%
Other	178	132	35%
Others (Incl contract Mfg.)	107	127	-16%
Total	1,856	1,708	9%

## **Consolidated Revenues for FY 2018-19**

			(`Crore)
Particulars	YTD 1819	YTD 1718	Gr%
India	3,234	2,351	38%
US	1,589	1,100	45%
Brazil	689	709	-3%
Germany	1,009	860	17%
Other	680	522	30%
Others (Incl contract Mfg.)	472	408	16%
Total	7,673	5,950	29%